JP4237497B2 - ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用 - Google Patents

ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用 Download PDF

Info

Publication number
JP4237497B2
JP4237497B2 JP2002576966A JP2002576966A JP4237497B2 JP 4237497 B2 JP4237497 B2 JP 4237497B2 JP 2002576966 A JP2002576966 A JP 2002576966A JP 2002576966 A JP2002576966 A JP 2002576966A JP 4237497 B2 JP4237497 B2 JP 4237497B2
Authority
JP
Japan
Prior art keywords
fluorophenyl
formula
pyrazolo
het
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002576966A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004525149A5 (enExample
JP2004525149A (ja
Inventor
アルベルティ,ミカエル,ジョン
チャンバーレイン,スタンリー,ディー
チュン,ムイ
ガドムンドソン,クリスチャン
ハリス,フィリップ,アンソニー
ジョンズ,ブライアン,エー.
ジュン,デイビッド,ケンドール
ピール,ミカエル,ロバート
スタンフォード,ジェニファー,バディアン
Original Assignee
スミスクライン ビーチャム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン ビーチャム コーポレーション filed Critical スミスクライン ビーチャム コーポレーション
Publication of JP2004525149A publication Critical patent/JP2004525149A/ja
Publication of JP2004525149A5 publication Critical patent/JP2004525149A5/ja
Application granted granted Critical
Publication of JP4237497B2 publication Critical patent/JP4237497B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2002576966A 2001-03-30 2002-03-20 ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用 Expired - Fee Related JP4237497B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28004701P 2001-03-30 2001-03-30
US30718901P 2001-07-23 2001-07-23
US30778601P 2001-07-25 2001-07-25
US31509001P 2001-08-27 2001-08-27
PCT/US2002/008524 WO2002078700A1 (en) 2001-03-30 2002-03-20 Pyralopyridines, process for their preparation and use as therapteutic compounds

Publications (3)

Publication Number Publication Date
JP2004525149A JP2004525149A (ja) 2004-08-19
JP2004525149A5 JP2004525149A5 (enExample) 2005-07-21
JP4237497B2 true JP4237497B2 (ja) 2009-03-11

Family

ID=27501267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002576966A Expired - Fee Related JP4237497B2 (ja) 2001-03-30 2002-03-20 ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用

Country Status (4)

Country Link
US (2) US7034030B2 (enExample)
EP (1) EP1372643A1 (enExample)
JP (1) JP4237497B2 (enExample)
WO (1) WO2002078700A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1377575B1 (en) * 2001-04-10 2006-07-05 SmithKline Beecham Corporation Antiviral pyrazolopyridine compounds
DE60222465T2 (de) * 2001-12-11 2008-06-05 Smithkline Beecham Corp. Pyrazolopyridin-derivate als antiherpesmittel
WO2003076441A1 (en) 2002-03-07 2003-09-18 Smithkline Beecham Corporation Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
US7153863B2 (en) * 2002-10-03 2006-12-26 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridline derivatives
WO2006128184A2 (en) * 2005-05-20 2006-11-30 Alantos-Pharmaceuticals, Inc. Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2432767B1 (en) * 2009-05-19 2013-06-26 Dow AgroSciences LLC Compounds and methods for controlling fungi
TW201102387A (en) * 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
PE20120493A1 (es) 2009-06-29 2012-05-20 Incyte Corp Pirimidinonas como inhibidores de pi3k
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
EP2402335A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
EP2402336A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
ES2764848T3 (es) 2010-12-20 2020-06-04 Incyte Holdings Corp N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Pi3k 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
PH12017501538B1 (en) 2015-02-27 2024-02-14 Incyte Holdings Corp Salts of p13k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
PT3377488T (pt) 2015-11-19 2022-11-21 Incyte Corp Compostos heterocíclicos como imunomoduladores
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3472167T3 (pl) 2016-06-20 2022-12-19 Incyte Corporation Związki heterocykliczne jako immunomodulatory
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MY197501A (en) 2016-12-22 2023-06-19 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102696516B1 (ko) 2016-12-22 2024-08-22 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체
EP4212529B1 (en) 2018-03-30 2025-01-29 Incyte Corporation Heterocyclic compounds as immunomodulators
FI4219492T3 (fi) 2018-05-11 2025-02-17 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
CN112469418A (zh) 2018-06-01 2021-03-09 因赛特公司 治疗pi3k相关病症的给药方案
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
BR112022002698A2 (pt) 2019-08-14 2022-07-19 Incyte Corp Compostos de imidazolil pirimidinilamina como inibidores de cdk2
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
PE20231438A1 (es) 2020-11-06 2023-09-14 Incyte Corp Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US485444A (en) * 1892-11-01 Check punching and marking machine
EP0151962A3 (en) * 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
GB8404584D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
GB8404586D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
US5002941A (en) 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5155114A (en) * 1989-01-23 1992-10-13 Fujisawa Pharmaceutical Company, Ltd. Method of treatment using pyrazolopyridine compound
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
WO1991000092A1 (en) 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
AU622330B2 (en) * 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
CA2084290A1 (en) 1990-06-12 1991-12-13 Jerry L. Adams Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
DE69232323T2 (de) 1991-01-29 2002-08-08 Fujisawa Pharmaceutical Co., Ltd. Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
GB9107513D0 (en) * 1991-04-10 1991-05-29 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5300478A (en) * 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
SK133297A3 (en) 1995-04-04 1998-07-08 Glaxo Group Ltd Imidazo[1,2-a]pyridine derivatives, pharmaceutical composition containing same and their use
AU6111796A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor
AU6269496A (en) 1995-06-12 1997-01-09 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotrien e b4 receptor antagonist for the treatment of infla mmations
US5700816A (en) 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
FR2757059B1 (fr) 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Nouvelle application therapeutique des derives du pyrrole
FR2757166B1 (fr) * 1996-12-12 1999-01-29 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
ATE281458T1 (de) 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US6136869A (en) * 1997-10-17 2000-10-24 Eastman Chemical Company Depolymerization process for recycling polyesters
CA2331878A1 (en) 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
FR2779724B1 (fr) 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa Derives du pyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent
TR200101208T2 (tr) 1998-11-03 2001-10-22 Glaxo Group Limited Seçici COX-2 inhibitörleri olarak pirazolopiridin türevleri
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
HUP0201789A3 (en) 1999-06-28 2003-12-29 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AUPQ969800A0 (en) 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
AU2002239344A1 (en) 2000-12-15 2002-06-24 Glaxo Group Limited Pyrazolopyridines
ATE300541T1 (de) 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridinderivate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
US6711762B2 (en) 2002-01-30 2004-03-30 Ktk Services, Inc. Method of using a truck cab bridge bed

Also Published As

Publication number Publication date
EP1372643A1 (en) 2004-01-02
US20060058319A1 (en) 2006-03-16
WO2002078700A1 (en) 2002-10-10
JP2004525149A (ja) 2004-08-19
US20050059677A1 (en) 2005-03-17
US7034030B2 (en) 2006-04-25
US7109209B2 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
JP4237497B2 (ja) ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
US7030134B2 (en) Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
JP2004525150A (ja) 治療用化合物としてのピラゾロピリジン類の使用
JP4219171B2 (ja) 抗ウイルス性ピラゾロピリジン化合物
EP1377573B1 (en) Pyrazolopyridine derivatives
EP1401836B1 (en) Imidazo¬1,2-a|pyridine derivatives for the prophylaxis and treatment of herpes viral infections
JP2006504728A (ja) ピラソロピリジン誘導体系治療用化合物
JP2005529919A (ja) 治療用化合物
JP2005507878A (ja) ヘルペス感染症を治療するためのピラゾロ−ピリジン類
EP1485385B1 (en) Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
US7199120B2 (en) Pyrazolo-pyridine derivatives as antiherpes agents

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20080819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20081125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081218

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111226

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees